Theralase Technologies Inc. V.TLT

RE:RE:RE:Finding Novel Drugs and M&A May 5th article..

[ScienceFirst]

I wouldn't hire Laserstock to negotiate a deal!  And I think he should stop talking ad nauseam about just this Endocyte deal if he wants to have a better picture of a much more accurate valuation.  I posted on 60+ examples, so we can better assess where we could stand.

He hopes a sub 2B$US by Novartis for TLT for the NMIBC indication, when Novartis paid 2.1B$US for something that only delays, not even destroys!!!

This below doesn't even compare with what TLT seems to be aiming for, if our data keeps delivering.
 

More than two years after splashing out $2.1 billion on Endocyte, Novartis is pulling the curtain on full phase 3 data for the radiopharmaceutical it picked up in that deal. 

The treatment, given alongside standard of care, added four months to the lives of patients with metastatic castration-resistant prostate cancer, helping them live a median of 15.3 months and reducing the risk of death by 38%. The combination nearly doubled the time patients had before their disease got worse, staving off cancer progression for a median of 8.7 months, while standard of care alone kept cancer at bay for 3.4 months.